Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly stock could soar 140% by 2028 as millions of Americans begin to take their GLP-1 weight loss drugs, according to Goldman Sachs. The firm estimated that if all GLP-1 trials succeed, 68 ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...

There is a downside associated with Lilly's meteoric rise, however. The company's stock is now trading at over 52 times projected earnings, making it the most expensive big pharma stock right now.

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...

Overall, Eli Lilly posted a solid Q2 and that also reflects in its stock price move. However, we think it’s appropriately valued at levels of over $900.

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world. It's one that ...

Eli Lilly's sales and profit growth has been impressive Eli Lilly has a solid roster of products in its portfolio already, with Mounjaro and Zepbound leading the charge.